Figure 4.
HDACis/Hsp90 inhibitors, PI3K/mTOR inhibitors, PIM kinase inhibitors, and MEK inhibitors target JAK2V617F or down-stream signaling molecules.
Reproduced by kind permission of Elsevier 2012.51
HDACis/Hsp90 inhibitors, PI3K/mTOR inhibitors, PIM kinase inhibitors, and MEK inhibitors target JAK2V617F or down-stream signaling molecules.
Reproduced by kind permission of Elsevier 2012.51